Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04844866
Title Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Miltenyi Biomedicine GmbH

diffuse large B-cell lymphoma

follicular lymphoma

marginal zone B-cell lymphoma

B-cell lymphoma

primary mediastinal B-cell lymphoma


Bendamustine + Polatuzumab vedotin-piiq + Rituximab

Gemcitabine + Oxaliplatin + Rituximab

Zamtocabtagene autoleucel

Age Groups: adult | senior
Covered Countries ITA | FRA | ESP | DEU | BEL | AUT

No variant requirements are available.